Market

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
Read More

Related Posts

‘I am increasingly resentful’: My husband of 10 years has $1 million and cars worth $200K. Why won’t he give me money?

‘I am increasingly resentful’: My husband of 10 years h...

Empire State Realty Trust declares Q4 dividend of $0.035 per share

Empire State Realty Trust declares Q4 dividend of $0.03...

DeNinno, Wabtec exec VP, sells $1.07 million in WAB stock

DeNinno, Wabtec exec VP, sells $1.07 million in WAB stock

‘Soon, all commodity charts will look like gold.’ BofA’s Hartnett goes bullish on commodities.

‘Soon, all commodity charts will look like gold.’ BofA’...

This Tesla move could help the EV maker shake a sales slump

This Tesla move could help the EV maker shake a sales s...

German industrial orders rise more than expected in October

German industrial orders rise more than expected in Oct...